Rapamycin derivatives

US12281125B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Simone BONAZZI · Cambridge, US
• Michael Connolly · Salem, US
• David Glass · Cambridge, US
• Manuel Mihalic · Wyhlen, DE
• Andrew W. Patterson · Somerville, US
• Silvio Roggo · Muttenz, CH
• Tea Shavlakadze · Cambridge, US
• Patrik Zueger · Basel, CH

Key dates

• Filing date: Dec 17, 2019
• Grant date: Apr 22, 2025
• Expiry date: Mar 21, 2042

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K45/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The disclosure provides 32-deoxo-rapamycin derivatives of Formula (I), or a pharmaceutically acceptable salt thereof, pharmaceutical compositions and pharmaceutical combinations comprising a compound of Formula (I), and methods of making same. Also provided herein are methods of using a compound of Formula (I) or a pharmaceutically acceptable salt thereof for treating the diseases and disorders described herein.